Showing 8241-8250 of 8689 results for "".
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitte
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according t
- Sciton Introduces NanoLaserPeelhttps://practicaldermatology.com/news/20140122-sciton_introduces_nanolaserpeel/2459365/Sciton introduced its new NanoLaserPeel, which the company says offers a faster, more comfortable alternative to microdermabrasion and light chemical peels. Sciton's Er:YAG NanoLaserPeel is designed t
- Rosacea Survey: Emotional Impact of Rosacea as Significant and Visible Signshttps://practicaldermatology.com/news/20140116-rosacea_survey_emotional_impact_of_rosacea_as_significant_and_visible_signs/2459371/The emotional impact of rosacea is often substantial regardless of subtype or severity, according to results of a new survey of 1,675 rosacea patients conducted by the National Rosacea Society. Among survey respondents who suffer from the facial redn
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.